Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma

NCT04152356 · clinicaltrials.gov ↗

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HepatoCellular Carcinoma

Interventions

DRUG: PD-1
DRUG: Sorafenib

Sponsor

Guangxi Medical University